Edvige Veneselli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Edvige Veneselli has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Elisa De Grandis
Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Member of the ERN EpiCARE, Genoa, Italy
2 shared publications - Giovanni Morana
Department of Neurosciences, University of Turin, Turin, Italy
2 shared publications - Maria Pintaudi
DINOGMI, University of Genova, 16147 Genoa, Italy
2 shared publications - Marisol Mirabelli-Badenier
Child Neuropsychiatry Unit, Department of Neurosciences and Rehabilitation, Istituto Giannina Gaslini, Genoa, Italy
2 shared publications Roberta Biancheri
2 shared publicationsAlberto Fois
1 shared publication
Latest Publications
- Open Access
- 28 April 2015
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 8 (1) , 1-6
Clinical and molecular characterization of a patient with interstitial 6q21q22.1 deletion
Interstitial 6q deletions, involving the 6q15q25 chromosomal region, are rare events characterized by variable phenotypes and no clear karyotype/phenotype correlation has been determined yet. We present a child with a 6q21q22.1 deletion, characterized by array-CGH, associated with developmental delay, intellectual disability, microcephaly, facial dysmorphisms, skeletal, muscle, and brain anomalies. In our patient, the 6q21q22.1 deleted region contains ten genes (TRAF3IP2, FYN, WISP3, TUBE1, LAMA4, MARCKS, HDAC2, HS3ST5, FRK, COL10A1) and two desert gene regions. We discuss here if these genes had some role in determining the phenotype of our patient in order to establish a possible karyotype/phenotype correlation.
- 28 April 2015
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 8 (1) , 1-6
Open AccessClinical and molecular characterization of a patient with interstitial 6q21q22.1 deletion
Interstitial 6q deletions, involving the 6q15q25 chromosomal region, are rare events characterized by variable phenotypes and no clear karyotype/phenotype correlation has been determined yet. We present a child with a 6q21q22.1 deletion, characterized by array-CGH, associated with developmental delay, intellectual disability, microcephaly, facial dysmorphisms, skeletal, muscle, and brain anomalies. In our patient, the 6q21q22.1 deleted region contains ten genes (TRAF3IP2, FYN, WISP3, TUBE1, LAMA4, MARCKS, HDAC2, HS3ST5, FRK, COL10A1) and two desert gene regions. We discuss here if these genes had some role in determining the phenotype of our patient in order to establish a possible karyotype/phenotype correlation.
- 16 February 2015
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 46 (02) , 104-109
Inferior Olivary Nucleus Involvement in Pediatric Neurodegenerative Disorders: Does It Play a Role in Neuroimaging Pattern-Recognition Approach?
The diagnostic work up of neurometabolic/degenerative disorders is complex. In such context, identification of neuroradiological features suggestive of specific diagnoses is useful to prompt further diagnostic tests. Involvement of the inferior olivary nucleus (ION) has been reported in several pathologic conditions, either as a primary manifestation of disease or secondary to hypertrophic olivary degeneration (HOD). In this study, we analyzed a cohort of 95 children with different neurometabolic/degenerative diseases involving the brainstem and cerebellum, with the aim to evaluate whether ION involvement plays a role in a neuroimaging-based pattern-recognition approach. A total of 13 patients (13.7%) showed bilateral high-signal intensity and enlargement of the ION on T2-weighted images, while 16 (16.8%) had ION T2-hyperintensity without olivary nucleus enlargement. Our study demonstrates that ION involvement is not rare in children with neurometabolic/degenerative disorders. Two main neuroradiological patterns, that is, “T2-hyperintense signal” and “T2-hyperintense signal with enlargement” are found. These patterns can be related to different etiologies, and do not suggest specific diagnoses. Primary ION lesion can be characterized by olivary swelling, and the differentiation from typical secondary HOD may be difficult.
- 16 February 2015
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 46 (02) , 104-109
Inferior Olivary Nucleus Involvement in Pediatric Neurodegenerative Disorders: Does It Play a Role in Neuroimaging Pattern-Recognition Approach?
The diagnostic work up of neurometabolic/degenerative disorders is complex. In such context, identification of neuroradiological features suggestive of specific diagnoses is useful to prompt further diagnostic tests. Involvement of the inferior olivary nucleus (ION) has been reported in several pathologic conditions, either as a primary manifestation of disease or secondary to hypertrophic olivary degeneration (HOD). In this study, we analyzed a cohort of 95 children with different neurometabolic/degenerative diseases involving the brainstem and cerebellum, with the aim to evaluate whether ION involvement plays a role in a neuroimaging-based pattern-recognition approach. A total of 13 patients (13.7%) showed bilateral high-signal intensity and enlargement of the ION on T2-weighted images, while 16 (16.8%) had ION T2-hyperintensity without olivary nucleus enlargement. Our study demonstrates that ION involvement is not rare in children with neurometabolic/degenerative disorders. Two main neuroradiological patterns, that is, “T2-hyperintense signal” and “T2-hyperintense signal with enlargement” are found. These patterns can be related to different etiologies, and do not suggest specific diagnoses. Primary ION lesion can be characterized by olivary swelling, and the differentiation from typical secondary HOD may be difficult.
- 1 March 2012
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 16 (2) , 192-195
Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments
- 1 March 2012
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 16 (2) , 192-195
Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments
- 25 February 2009
- Published by Springer Nature in neurogenetics
- Vol. 10 (3) , 241-250
Novel mutations in the CDKL5 gene, predicted effects and associated phenotypes
It has been found that CDKL5 gene mutations are responsible for early-onset epilepsy and drug resistance. We screened a population of 92 patients with classic/atypical Rett syndrome, 17 Angelman/Angelman-like patients and six idiopathic autistic patients for CDKL5 mutations and exon deletions and identified seven novel mutations: six in the Rett subset and one in an Angelman patient. This last, an insertion in exon 11, c.903_904 dupGA, p.Leu302Aspfx49X, is associated with a relatively mild clinical presentation as the patient is the only one capable of sitting and walking alone. Of the six mutations, two are de novo missense changes affecting highly conserved aminoacid residues, c.215 T > C p.Ile72Thr and c.380A > G p.His127Arg (present in a mosaic condition) found in two girls with the most severe clinical presentation, while the remaining are the splicing c.145 + 2 T > C and c.2376 + 5G > A, the c.1648C > T p.Arg550X and the MPLA-identified c.162_99del261 mutation. RNA characterisation of four mutations revealed the aberrant transcript of the missense allele (case 2) and not the stop mutation (case 3), but also allowed the splicing mutation (case 1) and the c.-162_99del261 (case 4) to be categorised as truncating. The obtained data reinforce the view that a more severe phenotype is due more to an altered protein than haploinsufficiency. Furthermore, the mutational repertoire of the CDKL5 gene is shown to be expanded by testing patients with phenotypical overlap to Rett syndrome and applying multiplex ligation-dependent probe amplification.
- 25 February 2009
- Published by Springer Nature in neurogenetics
- Vol. 10 (3) , 241-250
Novel mutations in the CDKL5 gene, predicted effects and associated phenotypes
It has been found that CDKL5 gene mutations are responsible for early-onset epilepsy and drug resistance. We screened a population of 92 patients with classic/atypical Rett syndrome, 17 Angelman/Angelman-like patients and six idiopathic autistic patients for CDKL5 mutations and exon deletions and identified seven novel mutations: six in the Rett subset and one in an Angelman patient. This last, an insertion in exon 11, c.903_904 dupGA, p.Leu302Aspfx49X, is associated with a relatively mild clinical presentation as the patient is the only one capable of sitting and walking alone. Of the six mutations, two are de novo missense changes affecting highly conserved aminoacid residues, c.215 T > C p.Ile72Thr and c.380A > G p.His127Arg (present in a mosaic condition) found in two girls with the most severe clinical presentation, while the remaining are the splicing c.145 + 2 T > C and c.2376 + 5G > A, the c.1648C > T p.Arg550X and the MPLA-identified c.162_99del261 mutation. RNA characterisation of four mutations revealed the aberrant transcript of the missense allele (case 2) and not the stop mutation (case 3), but also allowed the splicing mutation (case 1) and the c.-162_99del261 (case 4) to be categorised as truncating. The obtained data reinforce the view that a more severe phenotype is due more to an altered protein than haploinsufficiency. Furthermore, the mutational repertoire of the CDKL5 gene is shown to be expanded by testing patients with phenotypical overlap to Rett syndrome and applying multiplex ligation-dependent probe amplification.
- Open Access
- 1 January 2009
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 35 (1) , 23
Neonatal diabetes mellitus due to pancreatic agenesis and pervasive developmental disorder
Recent studies suggested a link between type 1 diabetes mellitus and pervasive developmental disorder. Moreover, permanent neonatal diabetes mellitus due to pancreatic agenesis can be associated with neurological deficit involving cerebellar functions, but no association with pervasive developmental disorder has been described so far. Clinical and neuropsychological evaluation of a child with pancreatic agenesis, mental retardation and pervasive developmental disorder is reported.
- 1 January 2009
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 35 (1) , 23
Open AccessNeonatal diabetes mellitus due to pancreatic agenesis and pervasive developmental disorder
Recent studies suggested a link between type 1 diabetes mellitus and pervasive developmental disorder. Moreover, permanent neonatal diabetes mellitus due to pancreatic agenesis can be associated with neurological deficit involving cerebellar functions, but no association with pervasive developmental disorder has been described so far. Clinical and neuropsychological evaluation of a child with pancreatic agenesis, mental retardation and pervasive developmental disorder is reported.
- 1 August 2001
- Published by Elsevier in Brain and Development
- Vol. 23 (5) , 306-311
Clinical and EEG findings in 18 cases of late infantile neuronal ceroid lipofuscinosis
- 1 August 2001
- Published by Elsevier in Brain and Development
- Vol. 23 (5) , 306-311
Clinical and EEG findings in 18 cases of late infantile neuronal ceroid lipofuscinosis
- 31 May 2001
- Published by Elsevier in Epilepsy Research
- Vol. 46 (1) , 27-32
Malignant migrating partial seizures in infancy
- 31 May 2001
- Published by Elsevier in Epilepsy Research
- Vol. 46 (1) , 27-32
Malignant migrating partial seizures in infancy